CClinicalTrials.gg
Sign In
Not yet recruitingNCT07844239Updated Sep 28, 2026

Direct Electrical Stimulation of Central Autonomic Network for Blood Pressure Control: a Mechanism Study

An interventional study of direct electrical stimulation in Blood Pressure Control and Hypertension, sponsored by Xuanwu Hospital, Beijing. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Xuanwu Hospital, Beijing · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The primary objective of this research is to study direct electrical stimulation of central autonomic network for blood pressure control.

Read the detailed description

This project aims to include 20 participants, and evaluate the direct electrical stimulation of central autonomic network for blood pressure control through A pilot, prospective clinical trial. It is expected to explore potential blood pressure regulation-related targets in the central autonomic neural network and provide a neuromodulation approach for the treatment of blood pressure disorders, including refractory hypertension and neurogenic orthostatic hypotension.

02

Conditions studied

  • Blood Pressure Control
  • Hypertension

Browse trials for

Keywords

  • blood pressure control
  • central autonomic neural network
  • direct electrical stimulation
  • hypertension
03

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Aged 18-60 years, with no gender restrictions.
  2. Free from severe systemic diseases.
  3. Patients who have undergone stereoelectroencephalography electrode implantation.
  4. Patients who have been informed of potential risks, consented to participate in this study, and signed the informed consent form.
  5. Daytime clinic blood pressure fluctuates within the following range: 90 mmHg \< systolic blood pressure \< 140 mmHg; 60 mmHg \< diastolic blood pressure \< 90 mmHg.

Exclusion criteria

Exclusion Criteria:

  1. Patients with scalp electrode hematoma or sub-electrode effusion after intracranial electrode implantation, who are unable to receive electrical stimulation.
  2. Patients with intracranial structural lesions (e.g., encephalomalacia foci, vascular malformations, space-occupying lesions, etc.).
  3. Pregnant women.
  4. Patients who are unable to cooperate due to mental disorders or other causes.
  5. Patients who have participated in other clinical trials within the past 3 months.
  6. Patients who apply to withdraw from this clinical trial for any reason.
  7. Patients with cardiac or pulmonary insufficiency.
  8. Patients with white coat effect are excluded.
  9. Patients with low cerebrovascular risk assessed by cranial magnetic resonance imaging (MRI).
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Direct electrical stimulation

    Patients with hypertension and drug-resistant focal epilepsy who underwent intracranial monitoring via stereotactically implanted depth electrodes (SEEG) are assigned to Direct electrical stimulation for 30 sec per mission.

    Other: direct electrical stimulation

Interventions

  • Otherdirect electrical stimulation

    The intervention consists of direct electrical stimulation delivered at three distinct frequencies (10 Hz, 50 Hz, and 120 Hz). A double-blind design will be employed to randomly assign one of these frequencies for a 30-second direct electrical stimulation session in each patient.

05

What researchers measure

Primary outcomes

  1. blood pressure

    Blood Pressure is defined as the blood pressure measurement obtained 30 minutes after the completion of direct electrical stimulation.

    Time frame: up to 4 hours

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07844239
Lead sponsor
Xuanwu Hospital, Beijing
Responsible party
Liankun_Ren (Professor, Xuanwu Hospital, Beijing) — Principal investigator
First posted
Sep 28, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 28, 2026

Study contacts

Liankun Ren, MD
Contact
renlk2022@outlook.com
+86 13681576621
Liankun Ren, MD
principal investigator · Xuanwu Hospital, Beijing

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hypertension→

Other studies from this sponsor

Xuanwu Hospital, Beijing

Start the discussion